cemiplimab
sanofi,regeneron
['hanna', 'cemiplimab']
study results presented at #asco23 of the first prospective study using the pd-1 inhibitor cemiplimab for kidney transplant recipients with advanced, incurable cutaneous squamous cell carcinoma. presented by dana-farber's glenn hanna, md 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090